News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
ALADDIN Education: Applications for the ALADDIN Education 360° rotation with the European Medicines Agency are now open
Photo taken from ALADDIN Education/LinkedIn
Feb 26, 2024, 15:38

ALADDIN Education: Applications for the ALADDIN Education 360° rotation with the European Medicines Agency are now open

ALADDIN Education posted on LinkedIn:

“Interested in gaining practical experience in regulatory affairs and drug development?

Applications for the ALADDIN Education 360° rotation with the European Medicines Agency are now open. Find out more.”

Source: ALADDIN Education/LinkedIn

 

ALADDIN Education ALADDIN Education 360° rotation cancer drug development European Medicines Agency OncoDaily Oncology regulatory affairs
Blog
Jul 3, 2024, 18:40
Leandro Duarte: The City Cancer Challenge Needs Assessment
Blog
Jul 3, 2024, 18:25
Amer Zeidan: Big data and quality of life measures to improve outcomes of MDS patients in iwMDS24 with talks from Spain
Blog
Jul 3, 2024, 18:13
Alessandro Di Federico: Intrapatient variation in PD-L1 and TMB
Blog
Jul 3, 2024, 18:00
Register by August 8 for the AACRMICR
Blog
Jul 3, 2024, 17:44
NextGen Grant for Transformative Cancer Research - AACR
Blog
Jul 3, 2024, 17:29
Benjamin Besse: Stop pembro after 2 years?
Insight
Jul 3, 2024, 17:15
Breast Cancer takeaways by Arya Roy from Upstate NY Cancer Symposium
Blog
Jul 3, 2024, 17:00
Impactful session on Colorectal Cancer by Arturo LoAIza-Bonilla
Insight
Jul 3, 2024, 15:58
Myeloma Paper of the Day, July 3rd, suggested by Robert Orlowski
Immune Oncology
Jul 3, 2024, 14:50
Understanding Side Effects of Cancer Immunotherapy
Blog
Jul 3, 2024, 14:48
Deep lamichhane: Cancer Surgery Workshop at Bhaktapur Cancer Hospital
Insight
Jul 3, 2024, 14:37
Jarushka Naidoo: Phase III RESILIENT Trial of Liposomal Irinotecan v Topotecan in 2L SCLC